The Ministry of Health of Russia has approved phase III clinical trials of Ambervin, a coronavirus drug for injections and inhalations developed by Promomed, a Russian pharmaceutical company. The information on the fact can be found in the state register of medicines.
“An open randomized multicenter comparative study to evaluate the efficacy, safety and tolerability of the use of Ambervin, a lyophilizate for the preparation of a solution for intravenous and intramuscular administration and a solution for inhalation (OOO “Promomed Rus”, Russia) in patients hospitalized with COVID-19,” the entry says.
According to the registry, the subjects of phase III clinical trials of the drug will be 350 patients in 10 Russian medical institutions; the phase will end on December 31, 2022.
